Navigation Links
Zogenix Reports FDA Provides New PDUFA Date for Sumavel(TM) DosePro(TM)
Date:2/18/2009

SAN DIEGO, Feb. 18 /PRNewswire/ -- Zogenix, Inc. ("Zogenix"), a private, specialty pharmaceutical company, announced that the U.S. Food & Drug Administration (FDA) has provided a target date of July 15, 2009 for completion of its review of the NDA for Sumavel DosePro (sumatriptan injection) needle-free delivery system. Zogenix is seeking marketing approval of Sumavel DosePro for the acute treatment of migraine attacks with or without aura, and the acute treatment of cluster headache episodes.

In October, the company received a Complete Response letter from the FDA citing the need for a single additional in vitro test to be conducted. Zogenix recently submitted this information to the FDA. The FDA has accepted this resubmission as a complete response, providing the new Prescription Drug User Fee Act (PDUFA) review date of July 15, 2009.

Sumavel DosePro uses the novel, proprietary DosePro drug delivery system to subcutaneously administer sumatriptan, a medication that has been used to treat migraines effectively and safely for over fifteen years, but without many of the issues associated with needle delivery. Sumavel DosePro has the potential of offering migraine relief beginning in as little as ten minutes, in a system sufferers can self administer in three easy steps. Given the unique attributes of Sumavel DosePro, Zogenix believes it has the potential to be used as a replacement for needle-based injectable forms of sumatriptan, as well as to replace tablet and nasal spray triptans for challenging migraine episodes.

Migraine affects approximately 30 million people in the United States. Patients suffer with extreme pain, nausea, vomiting, and sensitivity to light and sound, making it difficult to undertake work or other activities. Because of this, speed of relief is a key attribute identified by migraine patients when choosing a medication.

"We look forward to working w
'/>"/>

SOURCE Zogenix, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Senesco Technologies Reports Second Quarter Fiscal 2009 Financial Results
2. Gentiva Reports Fourth Quarter and Fiscal 2008 Results
3. Idenix Pharmaceuticals Reports Fourth Quarter and Year End Financial Results
4. Genesis Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2009
5. Pharmacyclics Reports Second Quarter Fiscal 2009 Financial Results
6. YM BIOSCIENCES REPORTS SECOND QUARTER 2009 OPERATIONAL AND FINANCIAL RESULTS
7. Shengtai Pharmaceutical, Inc. Reports Second Quarter Fiscal 2009 Financial Results
8. Neurobiological Technologies Reports Second Quarter Fiscal 2009 Financial Results
9. Corgenix Reports Second Quarter Fiscal 2009 Financial Results
10. Sigma-Aldrich (Nasdaq: SIAL) Reports Fourth Quarter Diluted EPS of $0.68. Ends 2008 With Record Sales and Earnings and Raises Quarterly Cash Dividend by 11.5%. Provides Outlook for 2009.
11. Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2008 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/30/2015)... MN , April 30, 2015 /PRNewswire/ - BioAmber ... producing sustainable chemicals, today announced that it has commenced an ... BioAmber expects to grant the underwriters a 30-day option ... the shares of common stock offered in the public ... there can be no assurance as to whether or ...
(Date:4/30/2015)... The following is an open letter sent April ... Blood Corp (NYSE: CO ) from Jayhawk Capital. ... directors of China Cord Blood Corp (" China Cord ") ... share from Golden Meditech Holdings Co Ltd ("Golden Med"). Certainly, ... benefit Golden Med and Mr. Kam, the Chairman of both ...
(Date:4/30/2015)... , April 30, 2015  Pfenex Inc. (NYSE ... the development of biosimilar therapeutics including high value ... closing of its previously announced underwritten public offering ... a public offering price of $15.50 per share. ... underwriters of their option to purchase up to ...
(Date:4/30/2015)... 30, 2015 WuXi PharmaTech (Cayman) Inc. ("WuXi" ... global contract R&D services provider, today announced that its ... letter, dated April 29, 2015, from a consortium (the ... "Chairman"), founder, chairman and chief executive officer of the ... proposes a transaction (the "Transaction") involving the acquisition of ...
Breaking Biology Technology:BioAmber Inc. Announces Public Offering Of Common Stock 2BioAmber Inc. Announces Public Offering Of Common Stock 3April 30, 2015 Open Letter to the Board of China Cord Blood Corp from Jayhawk Capital 2April 30, 2015 Open Letter to the Board of China Cord Blood Corp from Jayhawk Capital 3April 30, 2015 Open Letter to the Board of China Cord Blood Corp from Jayhawk Capital 4April 30, 2015 Open Letter to the Board of China Cord Blood Corp from Jayhawk Capital 5Pfenex Inc. Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares 2WuXi PharmaTech Announces Receipt of Proposal 2WuXi PharmaTech Announces Receipt of Proposal 3WuXi PharmaTech Announces Receipt of Proposal 4WuXi PharmaTech Announces Receipt of Proposal 5WuXi PharmaTech Announces Receipt of Proposal 6
... May 13 Xennex, Inc. (Xennex) announced today ... of Version 3.0 beta, available at ... 3.0 features a significantly upgraded infrastructure, including a ... and speedier search engine. It provides capabilities for ...
... OF INDUSTRY, Calif. and HONG KONG, May 13 ... that its 49% owned subsidiary, Excalibur International Marine Corporation, ... Taiwan Strait between Taiwan and Mainland China. Excalibur,s ... and is capable of carrying over 300 tons of ...
... DIEGO, May 12 Amylin Pharmaceuticals, Inc. (Nasdaq: ... Care Conference on Tuesday, May 19, 2009 at ... Daniel M. Bradbury, president and chief executive officer of Amylin ... session will be webcast, and a recording will be made ...
Cached Biology Technology:GeneCards(R) Version 3.0 Beta Released 2GeneCards(R) Version 3.0 Beta Released 3EFT BioTech Holdings, Inc.'s Subsidiary Receives First Permit to Cross Taiwan Strait 2EFT BioTech Holdings, Inc.'s Subsidiary Receives First Permit to Cross Taiwan Strait 3
(Date:4/1/2015)... 2015  NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... the growing mobile commerce market, announces the second shipment ... underway to early access pre-order customers. ... retail outlets including Walmart, Target, AT&T, Dunkin, Donuts, Stop ... accepted at all outlets and very easy to use. ...
(Date:3/30/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/lc9bnl/global_gesture ) has ... Market in Automotive Sector 2014-2018" report to their ... Recognition market in Automotive Sector to grow at a ... Gesture recognition is the ability of a device to ... Gesture recognition technology can be 2D-based or 3D-based. It ...
(Date:3/24/2015)... --  NexID Biometrics LLC, whose spoof-mitigation technology boosts ... the beginning of shipments of version 2.0 of its ... based in Potsdam, N.Y. , is ... began here today at the Walter E. Washington Convention ... SDK boosts the accuracy rate range to 96.5 to ...
Breaking Biology News(10 mins):NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 2NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 3NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 4Global Gesture Recognition Market in Automotive Sector Report 2015 - Growing Number of Partnerships 2NexID Begins Shipments Of Version 2.0 Fake-Finger-Detection Solution 2
... TORONTO A study led by scientists at The ... identifying drugs to treat children suffering from fatal cancers for ... developing a new drug from scratch, which is a complicated ... lab, they tested existing drugs on cancer stem cells from ...
... at Montana State University have developed six new biomedical ... infections, fungal infections and viral infections; boosting humans, innate ... The technologies are available for licensing to ... involves an existing clinical drug that was discovered to ...
... Market - Advanced Technologies, Global Forecast and Winning Imperatives... -- DALLAS, August 18, 2010 ... ... --> ... s = ,; var first_result; // Results are keyed by longUrl, so we need to grab ...
Cached Biology News:Scientists find new twist on drug screening to treat common childhood cancer 2Scientists find new twist on drug screening to treat common childhood cancer 3Montana State University offers 6 new biomedical technologies for licensing 2Montana State University offers 6 new biomedical technologies for licensing 3Montana State University offers 6 new biomedical technologies for licensing 4New Report - Bioinformatics Market - Advanced Technologies, Global Forecast and Winning Imperatives (2009 - 2014) By MarketsandMarkets 2New Report - Bioinformatics Market - Advanced Technologies, Global Forecast and Winning Imperatives (2009 - 2014) By MarketsandMarkets 3New Report - Bioinformatics Market - Advanced Technologies, Global Forecast and Winning Imperatives (2009 - 2014) By MarketsandMarkets 4New Report - Bioinformatics Market - Advanced Technologies, Global Forecast and Winning Imperatives (2009 - 2014) By MarketsandMarkets 5New Report - Bioinformatics Market - Advanced Technologies, Global Forecast and Winning Imperatives (2009 - 2014) By MarketsandMarkets 6New Report - Bioinformatics Market - Advanced Technologies, Global Forecast and Winning Imperatives (2009 - 2014) By MarketsandMarkets 7
... for interferons are cytopathic effect inhibition assays, also ... types include; tissue culture supernatents; serum from PK ... one unit is defined as the quantity of ... effect of viral infection by 50%. ...
... cytopathic effect inhibition assays, also known as CPE ... culture supernatents; serum from PK studies and delivery ... defined as the quantity of interferon required per ... infection by 50%. All standards used ...
... effect inhibition assays, also known as CPE and ... supernatents; serum from PK studies and delivery formulations. ... as the quantity of interferon required per milliliter ... by 50%. All standards used in ...
Request Info...
Biology Products: